| HOME >> BIOLOGY >> TECHNOLOGY |
8,695
—
8,69511,765
—
11,765Interest expense
(2,070)
—
(2,070)(2,216)
—
(2,216)Gain on contingent consideration
—
—
——
7,994
7,994Other-than-temporary impairment loss on equity investment
—
(39,482)
(39,482)—
—
—Other income (expense), net
(236)
—
(236)(177)
—
(177)Total other income (expense), net
6,389
(39,482)
(33,093)9,372
7,994
17,366Income before income tax
162,245
(69,088)
93,157158,753
(3,542)
155,211Income tax expense
49,226
(6,193)
43,03351,303
(3,029)
48,274Net income
$113,019
$ (62,895)
$ 50,124$107,450
$ (513)
$106,937Net income per share:Basic
$ 2.39
$ (1.33)
$ 1.06$ 2.21
$ (0.01)
$ 2.20Diluted
$ 2.34
$ (1.30)
$ 1.04$ 2.19
$ (0.01)
$ 2.18Weighted average shares outstanding:Basic
47,25447,25448,56048,560Diluted
48,38748,38749,03349,033Gen-Probe IncorporatedConsolidated Statements of Cash Flows - GAAP(In thousands)
(Unaudited)Twelve Months EndedDecember 31,20112010Operating activities:Net income
$ 50,124$ 106,937Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization
46,56944,529Amortization of premiums on investments, net of accretion of discounts
9,5929,573Stock-based compensation
24,74124,075Excess tax benefit from employee stock-based compensation
(5,080)(3,692)Deferred revenue
850(1,808)Deferred income tax
(4,220)(3,745)Other
'/>"/>
| SOURCE Gen-Probe Incorporated Copyright©2010 PR Newswire. All rights reserved |